ID27833A - METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA - Google Patents

METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA

Info

Publication number
ID27833A
ID27833A IDW20010626A ID20010626A ID27833A ID 27833 A ID27833 A ID 27833A ID W20010626 A IDW20010626 A ID W20010626A ID 20010626 A ID20010626 A ID 20010626A ID 27833 A ID27833 A ID 27833A
Authority
ID
Indonesia
Prior art keywords
aterosclelerosis
inhibitors
combinations
treatment
methods
Prior art date
Application number
IDW20010626A
Other languages
English (en)
Indonesian (id)
Inventor
Jeffry A Robl
Rex A Parker
Scott A Biller
Haris Jamil
Bruce L Jacobson
Krishna Kudukula
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27833(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ID27833A publication Critical patent/ID27833A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20010626A 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA ID27833A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10067798P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
ID27833A true ID27833A (id) 2001-04-26

Family

ID=22280975

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW20010626A ID27833A (id) 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA
IDW20010624A ID28450A (id) 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI DIABETES DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA

Family Applications After (1)

Application Number Title Priority Date Filing Date
IDW20010624A ID28450A (id) 1998-09-17 1999-09-13 METODA UNTUK MENGOBATI DIABETES DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA

Country Status (30)

Country Link
US (1) US20020035064A1 (cs)
EP (2) EP1113801A4 (cs)
JP (2) JP2002524518A (cs)
KR (2) KR20010075150A (cs)
CN (2) CN1317970A (cs)
AT (1) ATE406898T1 (cs)
AU (2) AU754488B2 (cs)
BG (2) BG105431A (cs)
BR (2) BR9913833A (cs)
CA (2) CA2344300A1 (cs)
CO (2) CO5130025A1 (cs)
CZ (2) CZ2001965A3 (cs)
DE (1) DE69939481D1 (cs)
EE (2) EE200100155A (cs)
ES (1) ES2311306T3 (cs)
GE (2) GEP20033044B (cs)
HU (2) HUP0104240A2 (cs)
ID (2) ID27833A (cs)
IL (2) IL141786A0 (cs)
LT (2) LT4870B (cs)
LV (2) LV12687B (cs)
NO (2) NO20011352L (cs)
NZ (2) NZ510209A (cs)
PE (2) PE20001056A1 (cs)
PL (2) PL346661A1 (cs)
SK (1) SK3202001A3 (cs)
TR (2) TR200100774T2 (cs)
UY (2) UY25714A1 (cs)
WO (2) WO2000015230A1 (cs)
ZA (2) ZA200207433B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259459T3 (es) * 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited Nuevos inhibidores de apoptosis.
AU2005201289B2 (en) * 1999-02-12 2008-04-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
WO2000047734A1 (en) * 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CA2396596A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
HUP0500543A2 (hu) 2000-11-20 2005-09-28 Bristol-Myers Squibb Company Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
EP1385549A2 (en) * 2001-03-12 2004-02-04 Novartis AG Combination of nateglinide or repaglinide with at least one further antidiabetic compound
WO2003006023A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Company Pyrazinone inhibitors of fatty acid binding protein and method
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
DE602004030318D1 (de) 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
EP1620089A4 (en) * 2003-03-26 2008-12-24 Crc For Asthma Ltd Therapeutic and prophylactic compositions and their uses
WO2004096977A2 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
ATE395338T1 (de) 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
BRPI0607688A2 (pt) 2005-02-17 2009-09-22 Synta Pharmaceuticals Corp método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto
AU2006276072A1 (en) 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
CA2626441A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
EP2037929A4 (en) * 2006-06-02 2010-02-17 Univ San Diego State Res Found COMPOSITIONS AND METHODS FOR REDUCING HYPERLIPIDEMIA
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
JP2012508692A (ja) * 2008-11-12 2012-04-12 シェーリング コーポレイション 脂肪酸結合タンパク質（ｆａｂｐ）の阻害薬
CA2753991C (en) 2009-03-05 2019-11-05 President And Fellows Of Harvard College Secreted ap2 and methods of inhibiting same
JP6223376B2 (ja) 2014-03-24 2017-11-01 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6514282B2 (ja) * 2014-03-24 2019-05-15 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
JP2018515082A (ja) 2015-04-30 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 代謝障害を処置するための抗ａｐ２抗体及び抗原結合剤
WO2018005551A1 (en) * 2016-06-27 2018-01-04 President And Fellows Of Harvard College Compounds useful to treat metabolic disorders
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
MX2023000036A (es) 2020-06-27 2023-02-01 Crescenta Biosciences Composicion de compuestos que modulan el metabolismo celular y metodos de uso.
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
FR2156486A1 (en) 1971-10-22 1973-06-01 Roussel Uclaf Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (cs) 1974-06-07 1981-03-18
GB1507032A (en) 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
DE3817375C2 (de) 1987-05-22 1997-04-30 Squibb & Sons Inc Phosphorhaltige HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr) 1990-06-14 1994-05-06 Bellon Laboratoires Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de) 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR100345943B1 (ko) * 1993-12-20 2002-11-30 후지사와 야꾸힝 고교 가부시키가이샤 4,5-디아릴옥사졸유도체
US5599770A (en) 1994-07-15 1997-02-04 Kureha Kagaku Kogyo Kabushiki Kaisha Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk) 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en) 1996-01-05 1996-03-06 Foster Wheeler Petrol Dev Ltd Spacing bouy for flexible risers
AUPO134596A0 (en) 1996-08-01 1996-08-22 Jal Pastoral Co. Pty Ltd Demountable article carrier for motor vehicles
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
US20020035064A1 (en) 2002-03-21
PE20001047A1 (es) 2000-12-24
CN1319012A (zh) 2001-10-24
DE69939481D1 (de) 2008-10-16
WO2000015230A1 (en) 2000-03-23
LT2001023A (en) 2001-08-27
KR20010079842A (ko) 2001-08-22
LV12687B (lv) 2001-10-20
BG105431A (en) 2001-12-29
PE20001056A1 (es) 2000-12-24
AU755563B2 (en) 2002-12-12
UY25713A1 (es) 2001-08-27
NO20011351L (no) 2001-05-11
JP2002524517A (ja) 2002-08-06
SK3202001A3 (en) 2002-04-04
CA2344309A1 (en) 2000-03-23
NZ510207A (en) 2003-08-29
EP1113801A1 (en) 2001-07-11
IL141785A0 (en) 2002-03-10
BR9913833A (pt) 2001-05-29
GEP20033045B (en) 2003-08-25
UY25714A1 (es) 2001-08-27
ID28450A (id) 2001-05-24
EP1121129A1 (en) 2001-08-08
PL346660A1 (en) 2002-02-25
CO5130025A1 (es) 2002-02-27
IL141786A0 (en) 2002-03-10
WO2000015229A1 (en) 2000-03-23
EP1121129B1 (en) 2008-09-03
LV12686A (en) 2001-07-20
EE200100155A (et) 2002-08-15
NO20011352D0 (no) 2001-03-16
ATE406898T1 (de) 2008-09-15
ES2311306T3 (es) 2009-02-01
CZ2001964A3 (cs) 2002-01-16
LT4871B (lt) 2001-12-27
LV12686B (lv) 2001-10-20
EE200100154A (et) 2002-12-16
ZA200207433B (en) 2003-10-27
AU754488B2 (en) 2002-11-14
EP1121129A4 (en) 2002-10-16
PL346661A1 (en) 2002-02-25
CN1317970A (zh) 2001-10-17
EE04356B1 (et) 2004-10-15
AU6387799A (en) 2000-04-03
ZA200207430B (en) 2003-09-16
BR9913831A (pt) 2001-05-29
CA2344300A1 (en) 2000-03-23
TR200100774T2 (tr) 2001-12-21
GEP20033044B (en) 2003-08-25
CZ2001965A3 (cs) 2002-02-13
LT4870B (lt) 2001-12-27
BG105432A (en) 2001-12-29
EP1113801A4 (en) 2002-10-02
NO20011351D0 (no) 2001-03-16
HUP0104108A2 (hu) 2002-03-28
TR200100773T2 (tr) 2001-07-23
NZ510209A (en) 2003-07-25
JP2002524518A (ja) 2002-08-06
CO5130026A1 (es) 2002-02-27
HUP0104240A2 (hu) 2002-03-28
KR20010075150A (ko) 2001-08-09
AU6143799A (en) 2000-04-03
LT2001022A (en) 2001-08-27
NO20011352L (no) 2001-05-11
LV12687A (en) 2001-07-20

Similar Documents

Publication Publication Date Title
ID27833A (id) METODA UNTUK MENGOBATI ATEROSKLEROSIS DENGAN MENGGUNAKAN INHIBITOR aP2 DAN KOMBINASINYA
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
BR9714364A (pt) Amidas inibidoras da secreção de apo b/mtp
BG101717A (bg) Инхибитори на микрозомалния триглицерид пренасящ белтък и метод
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
EA199800988A1 (ru) Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
FI944926L (fi) Entsymaattinen hydroksylaatiomenetelmä HMG-CoA-reduktaasi-inhibiittorien ja niiden välituotteiden valmistamiseksi
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EP1466623A4 (en) CURE AGAINST ARTHRITIS
MY140504A (en) Statin-mmp inhibitor combinations
BR0112460A (pt) Método para tratamento de sépsis
ATE234800T1 (de) Verfahren zur synthese von taxanen
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
BR9807920A (pt) Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
IT1255470B (it) Composti attivi come inibitori dell&#39;enzima hmg-coa reduttasi
ECSP992885A (es) Combinaciones de estatina-inhibidor de mmp
AR010987A1 (es) Composicion farmaceutica y metodo para tratar un trastorno compulsivo.
ECSP961804A (es) Nuevos compuestos monociclicos de b -.lactama